Home>>Signaling Pathways>> Microbiology & Virology>> Influenza virus>>Rimantadine

Rimantadine

Catalog No.GC17819

anti-influenza virus drug

Products are for research use only. Not for human use. We do not sell to patients.

Rimantadine Chemical Structure

Cas No.: 13392-28-4

Size Price Stock Qty
25mg
$48.00
Ship Within 10-14 Days
50mg
$82.00
Ship Within 10-14 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Rimantadine (Flumadine) is an anti-influenza virus drug.Target: Influenza Virusrimantadine are oral antiviral drugs useful in the prophylaxis and treatment of influenza A virus infections. rimantadine has prophylactic efficacy comparable to amantadine but lower potential for causing adverse effects [1]. double-blind study of children with influenza-like illness. 37 received rimantadine for five days. Of the total 37 children in the rimantadine group, 27% were found to have resistant isolated compared with 6% in the total group receiving acetaminophen (P < .04). Furthermore, the mean inhibitory concentration of rimantadine increased with time in the rimantadine group (r = .4, P = .002) [2].

References:
[1]. Tominack, R.L. and F.G. Hayden, Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am, 1987. 1(2): p. 459-78.
[2]. Hall, C.B., et al., Children with influenza A infection: treatment with rimantadine. Pediatrics, 1987. 80(2): p. 275-82.

Reviews

Review for Rimantadine

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Rimantadine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.